Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Astellas making leadership changes in Canada and U.S.

Steve Sabus was named general manager of Astellas Pharma Canada (APCA), effective April 1, 2018. In his new role, he will lead business operations in the country.

Read More »

Perrigo appoints Uwe Röhrhoff president and CEO

Uwe Röhrhoff was named CEO of Perrigo Company following the retirement of John T. Hendrickson.

Read More »

Taiho Oncology appoints new president

Timothy Whitten has become president of Taiho Oncology Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co. Ltd. (Japan).

Read More »

New chief medical officer for Neurocrine Biosciences

Christopher O’Brien, M.D., chief medical officer of Neurocrine Biosciences Inc., retired in February 2018 after a transition period with his successor.

Read More »

Agency Exec Shaun Urban Joins Inception Companies

Shaun Urban was named president of the Inception Companies.

Read More »

People on the Move: Specialty Pharma Companies

Wayne Swanton was promoted to executive VP, Global Operations, at Allergan Plc following notification that Rob Stewart, executive VP and chief operating officer, intended to leave Allergan to become president and CEO of Amneal Pharmaceuticals.

Read More »

People on the Move: Biotechnology Companies

Anu Balendran, Ph.D., was appointed VP Business Development at Alligator Bioscience.

Read More »

People on the Move: Service Companies

Michael Mulhern joined AMRI as CEO, succeeding William S. Marth.

Read More »

CVS launches care program to manage cost of RA

CVS Health introduced Transform Rheumatoid Arthritis Care to help the company’s pharmacy benefit management clients better manage care and costs for rheumatoid arthritis. The program is the latest addition to the company’s suite of condition-specific, highly personalized Transform Care programs and adds value-based management strategies including outcomes-based contracts and a new indication-based formulary for autoimmune conditions to CVS Health’s integrated pharmacy care model

Read More »

PBM signs on Jardiance for outcomes-based contract

As part of its CareCentered Contracting program, pharmacy benefit manager Prime Therapeutics LLC entered into an outcomes-based contract with Boehringer Ingelheim for Jardiance, an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom